

21st July 2026

Eastbourne District General Hospital

Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500
Website: www.esht.nhs.uk

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

1) **How many patients were initiated on Ruxolitinib (Jakavi) in the past 6 months for the following conditions? (Patients are classed as initiated if they have not received any of the above treatments in the previous 6 months)**

- | | |
|---|---|
| a) Myelofibrosis (ICD10 code D47.4) | 9 |
| b) Polycythaemia Vera (ICD10 code D45) | 0 |
| c) Graft vs Host Disease (GvHD) (ICD10 code T86.0 or D89.8) (SNOMED Code: SCTID: 234646005) | |

East Sussex Healthcare NHS Trust does not treat patients for GvHD. These patients are referred to King's College Hospital NHS Foundation Trust. Please contact King's College Hospital directly for a response to this part of your request, via the email address below:

kch-tr.foi@nhs.net

2) **How many patients were initiated with the following regimens for any condition in the past 6 months? (Patients are classed as initiated if they have not received any of the above treatments in the previous 6 months)**

- | | |
|----------------|---|
| a) Momelotinib | 2 |
| b) Fedratinib | 0 |

3) **How many patients were treated in the past 6 months for Polycythaemia Vera (ICD10 code D45) with?**

- | | |
|-----------------------|---|
| a) Hydroxycarbamide | 7 |
| b) Interferon therapy | 0 |

- 4) Of the myelofibrosis (ICD10 D47.4) patients receiving the following treatments in the past 6 months, please indicate how many were receiving their first systemic therapy

(First systemic therapy = patient has not previously received any drug treatment for myelofibrosis, including hydroxycarbamide, interferon therapy, JAK inhibitors, or other systemic therapy. Excludes a watch and wait approach.)

Treatment	First systemic therapy	Received prior systemic therapy
Ruxolitinib (Jakavi)	2	6
Fedratinib (Inrebic)	0	0
Momelotinib (Omjjara)	0	5

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an internal review, please write to the Freedom of Information Team at esh-tr.foi@nhs.net quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team
East Sussex Healthcare NHS Trust
0300 131 4716
Core Hours of Business: Monday to Friday 9.00am to 4.00pm